Alliance Management Consulting and Training, Partnering Frameworks and Tools, Collaborative Leadership

Measuring What Matters Creates Winners
1. Partnering Guide / May 17th, 2021
How do you know if your alliance or business partnership is operating effectively? Sure, revenue is a gauge, as well as hitting key development milestones. It still doesn’t tell you if the partners are productively leveraging the resources available to the alliance, or if it is operating in an environment built on mutual trust and respect, focused on innovating and producing results.

Alliances are inherently inefficient and it is the job of the alliance professionals managing the alliance to preserve and enhance the value intended when entering into the collaboration, while identifying and mitigatin
g the risks that can cause it to fall short of its potential.

To measure if an alliance is operating effectively, many years ago we created the VitalSigns Alliance Operations Effectiveness Assessment (See Figure 1). In a demonstration that measuring effectiveness can contribute to alliance success, the XTANDI alliance of Astellas and Pfizer recently won the 2021 ASAP Alliance Excellence Award for a Longstanding Alliance. In accepting the award, the alliance directors credited the role regularly measuring effectiveness as part of a program of continuous improvement plays in the alliance’s success. Our congratulations to the winners! They have worked very hard over many years to ensure the alliance is producing maximum value for patients and the partners.

Measurin...
How to Tame an Octopus: Managing the Proliferation of Clinical Collaborations
1. Partnering Guide / October 15th, 2018
In 2016, former US President Jimmy Carter announced that he no longer required treatment for his metastatic melanoma that had spread to his brain and liver. After six months of being treated with the immunotherapy pembrolizumab (trade name KEYTRUDA), together with surgery and radiation therapy, doctors had seen no sign of his disease for three months. This was a remarkable development—before pembrolizumab was approved in 2011, President Carter’s cancer likely would have been fatal.

Known as a “checkpoint inhibitor” pembrolizumab and other drugs in its class work—in simplest terms—by turbocharging the body’s immune system so that it can fight cancer. Its success, and the success of other similar drugs, such as avelumab (trade name BAVENCIO), and nivolumab (trade name OPDIVO), have unleashed a tsunami of clinical collaborations to identify how using these drugs in combination might expand and extend their significant patient benefits—and maximize their value to the biopharma companies that are de...
Taming the Octopus: Managing the Web of Clinical Collaborations
4. News and Events / July 1st, 2018
Jan Twombly, president of The Rhythm of Business is joined by Judy Baselice, director, alliance management at Pfizer and Ellen Locker, executive director, alliance management Merck & Co. at the 2018 ASAP Biopharma Conference in an interactive discussion about the complex web of agreements, restrictions, and obligations resulting from the explosion of clinical collaborations to create combination therapies....
Top